Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients with Advanced Non Small Cell Lung Cancer (NSCLC)

Trial Profile

Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients with Advanced Non Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2016 Results (n=272) assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
    • 23 May 2013 Planned End Date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 23 May 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top